SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma - PubMed (original) (raw)

Bianca-Sabrina Targosz, Simone Lemeer, Ruth Eichner, Christian Langer, Lars Bullinger, Clemens Reiter, Julia Slotta-Huspenina, Sonja Schroeder, Anna-Maria Knorn, Julia Kurutz, Christian Peschel, Michele Pagano, Bernhard Kuster, Florian Bassermann

Affiliations

• PMID: 23263282
• DOI: 10.1038/ncb2651

SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma

Vanesa Fernández-Sáiz et al. Nat Cell Biol. 2013 Jan.

Abstract

The Tel2 (also known as Telo2) and Tti1 proteins control the cellular abundance of mammalian PIKKs and are integral components of mTORC1 and mTORC2. Here we report that Tel2 and Tti1 are targeted for degradation within mTORC1 by the SCFFbxo9 ubiquitin ligase to adjust mTOR signalling to growth factor availability. This process is primed by CK2, which translocates to the cytoplasm to mediate mTORC1-specific phosphorylation of Tel2/Tti1, subsequent to growth factor deprivation. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation whereas relief of feedback inhibition activates the PI(3)K/TORC2/Akt pathway to sustain survival. Significantly, primary human multiple myelomas exhibit high levels of Fbxo9. In this setting, PI(3)K/TORC2/Akt signalling and survival of multiple myeloma cells is dependent on Fbxo9 expression. Thus, mTORC1-specific degradation of the Tel2 and Tti1 proteins represents a central mTOR regulatory mechanism with implications in multiple myeloma, both in promoting survival and in providing targets for the specific treatment of multiple myeloma with high levels of Fbxo9 expression.

PubMed Disclaimer

Similar articles

• Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.
  Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, Iemura S, Natsume T, Mizushima N. Kaizuka T, et al. J Biol Chem. 2010 Jun 25;285(26):20109-16. doi: 10.1074/jbc.M110.121699. Epub 2010 Apr 28. J Biol Chem. 2010. PMID: 20427287 Free PMC article.
• CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability.
  Horejsí Z, Takai H, Adelman CA, Collis SJ, Flynn H, Maslen S, Skehel JM, de Lange T, Boulton SJ. Horejsí Z, et al. Mol Cell. 2010 Sep 24;39(6):839-50. doi: 10.1016/j.molcel.2010.08.037. Mol Cell. 2010. PMID: 20864032
• mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8.
  Kim SJ, DeStefano MA, Oh WJ, Wu CC, Vega-Cotto NM, Finlan M, Liu D, Su B, Jacinto E. Kim SJ, et al. Mol Cell. 2012 Dec 28;48(6):875-87. doi: 10.1016/j.molcel.2012.09.029. Epub 2012 Nov 8. Mol Cell. 2012. PMID: 23142081 Free PMC article.
• Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
  Zou Z, Chen J, Yang J, Bai X. Zou Z, et al. Curr Cancer Drug Targets. 2016;16(4):288-304. doi: 10.2174/1568009616666151113120830. Curr Cancer Drug Targets. 2016. PMID: 26563881 Review.
• The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
  Yoon MS. Yoon MS. Nutrients. 2017 Oct 27;9(11):1176. doi: 10.3390/nu9111176. Nutrients. 2017. PMID: 29077002 Free PMC article. Review.

Cited by

• Profiling of circadian genes expressed in the uterus endometrial stromal cells of pregnant rats as revealed by DNA microarray coupled with RNA interference.
  Tasaki H, Zhao L, Isayama K, Chen H, Nobuhiko Yamauchi, Yasufumi Shigeyoshi, Hashimoto S, Hattori MA. Tasaki H, et al. Front Endocrinol (Lausanne). 2013 Jul 8;4:82. doi: 10.3389/fendo.2013.00082. eCollection 2013. Front Endocrinol (Lausanne). 2013. PMID: 23847593 Free PMC article.
• Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9.
  Luo X, Wang Y, Zhang H, Chen G, Sheng J, Tian X, Xue R, Wang Y. Luo X, et al. Biomolecules. 2023 Nov 30;13(12):1724. doi: 10.3390/biom13121724. Biomolecules. 2023. PMID: 38136595 Free PMC article.
• Genome-Wide Association Study of Tacrolimus Pharmacokinetics Identifies Novel Single Nucleotide Polymorphisms in the Convalescence and Stabilization Periods of Post-transplant Liver Function.
  Liu Y, Zhang C, Li L, Ou B, Yuan L, Zhang T, Fan J, Peng Z. Liu Y, et al. Front Genet. 2019 May 31;10:528. doi: 10.3389/fgene.2019.00528. eCollection 2019. Front Genet. 2019. PMID: 31214251 Free PMC article.
• Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.
  Manni S, Carrino M, Piazza F. Manni S, et al. J Hematol Oncol. 2017 Oct 2;10(1):157. doi: 10.1186/s13045-017-0529-5. J Hematol Oncol. 2017. PMID: 28969692 Free PMC article. Review.
• FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
  Sperk A, Gabriel A, Koch D, Augsburger A, Sanchez V, Brockelt D, Öllinger R, Engleitner T, Giansanti P, Ludwig R, Auf der Maur P, Walter W, Haferlach T, Jeremias I, Rad R, Steigenberger B, Kuster B, Eichner R, Bassermann F. Sperk A, et al. Leukemia. 2024 Sep;38(9):2027-2031. doi: 10.1038/s41375-024-02345-0. Epub 2024 Jul 16. Leukemia. 2024. PMID: 39014197 Free PMC article. No abstract available.

References

1. 1. J Biol Chem. 2010 Jun 25;285(26):20109-16 - PubMed
2. 1. Science. 2011 Jun 10;332(6035):1322-6 - PubMed
3. 1. Genes Dev. 2010 Sep 15;24(18):2019-30 - PubMed
4. 1. Oncogene. 2005 Apr 7;24(15):2461-73 - PubMed
5. 1. Blood. 2007 Feb 15;109(4):1692-700 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • BioCyc
  • Gene Ontology
  • GlyGen glycoinformatics resource
  • IMEx Consortium

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal